Clinical Trials Logo
  1. Home
  2. Non-Hodgkin's Lymphoma
  3. NCT00834951
  4. Details
NCT00834951 Clinical Trial

Adjuvant Low Dose Total Body Irradiation in Elderly Patients With Diffuse Large B-Cell Lymphoma

Non Hodgkin's Lymphoma Clinical Trial

Official title:
A Prospective Multicenter Phase II Study of MabThera (Rituximab) Plus 2 Weekly CHOP Followed by Low Dose Total Body Irradiation in Elderly Patients With Diffuse Large B-Cell Lymphoma

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00834951
Other study ID # LTBI-NHL-01
Secondary ID
Status Completed
Phase Phase 2
First received February 2, 2009
Last updated February 2, 2009
Start date January 2003
Est. completion date December 2008

Study information
Verified date February 2009
Source University of Aarhus
Contact n/a
Is FDA regulated No
Health authority Denmark: Ethics Committee
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine whether the application of low dose total body irradiation following chemo-immuntherapy in elderly patients with aggressive with non-Hodgkin's lymphoma would be safe and potentially benecicial adjuvant therapy

Recruitment information / eligibility
Status Completed
Enrollment 40
Est. completion date December 2008
Est. primary completion date December 2007
Accepts healthy volunteers No
Gender Both
Age group 60 Years and older
Eligibility Inclusion Criteria:

- previously untreated, pathology verified aggressive non-Hodgkin lymphoma of the diffuse large B-cell type according to the WHO classification. Age between 60 years and 80 years.Positive for an anti-CD20 antibody. Good performance status and normal initial normal blood count.

Exclusion Criteria:

- Patients with previous lymphoma associated with immune suppression of any sort. Diagnosis or history of indolent lymphoma or other malignancies. Marked impairment of any vital organ such as the heart, lung, liver or kidneys.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Radiation:
• Low dose total body irradiation
Low dose total body irradiation is given 3 weeks after the end of chemo-immunetherapy in the form of 4 daily fractions 0.2 Gy per fraction to be repeated after 2 weeks of rest

Locations
Country Name City State
n/a

Sponsors (3)
Lead Sponsor Collaborator
University of Aarhus Aarhus University Hospital, Rigshospitalet, Denmark
See also
  Status Clinical Trial Phase
Recruiting NCT06014073 - TRAC and Power3 Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL Phase 1/Phase 2
Recruiting NCT02007811 - Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination Phase 1/Phase 2
Terminated NCT00909948 - Intentional Rejection of the Donor Graft Using Recipient Leukocyte Infusion(s) Following Nonmyeloablative Allogeneic Stem Cell Transplant Phase 1
Completed NCT00665314 - Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM). Phase 2
Recruiting NCT05370547 - Chidamide Bridging for CAR-T Therapy Phase 1/Phase 2
Recruiting NCT06285422 - Study Evaluating SC262 in Subjects With r/r B-cell Malignancies (VIVID) Phase 1
Withdrawn NCT01101581 - Study of Veltuzumab and 90Y-Epratuzumab in Relapsed/Refractory, Aggressive NHL Phase 1/Phase 2
Completed NCT00477945 - Phase I Trial of Clofarabine in Combo w/ HD Etoposide & Cyclophosphamide and APBSCT for Pts w/ High-Risk or Refractory NHL Phase 1
Terminated NCT00038818 - CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell Transplantation N/A
Withdrawn NCT01789723 - Phase 1 Study of Fusilev to Prevent or Reduce Mucositis in Patients With Non-Hodgkin's Lymphoma Receiving Folotyn Phase 1
Completed NCT00013533 - Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies Early Phase 1
Completed NCT01610180 - Eltrombopag for the Treatment of Immune ThrombocytoPenia (ITP) Secondary to Chronic Lymphoproliferative Disorders (LPDs) Phase 2
Terminated NCT00714259 - Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies Phase 2/Phase 3
Completed NCT01018758 - Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy Phase 2
Completed NCT00001830 - Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants Phase 1
Recruiting NCT01063439 - BuEAM Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat Diffuse Large B Cell Lymphoma (DLCBL) Phase 2
Completed NCT01527422 - Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Rituximab Pateinets With Aggresive NHL Phase 1/Phase 2
Recruiting NCT04497688 - Evaluate the Efficacy and Safety of PEG-rhG-CSF in Preventing Neutropenia After Chemotherapy in Patients With Non-Hodgkin's Lymphoma N/A
Completed NCT00597714 - Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant Phase 2
Completed NCT00001430 - A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas Phase 2